Structure Therapeutics (GPCR) Net Income (2022 - 2026)

Structure Therapeutics' Net Income history runs 5 years deep, the most recent figure standing at -$76.0 million for Q1 2026.

• In Q1 2026, Net Income fell 62.21% year-over-year to -$76.0 million; the TTM figure through Mar 2026 stood at -$26.3 million (up 80.43% YoY), while the FY2025 annual figure was $2.9 million, up 102.53% from the prior year.
• Net Income was -$76.0 million for Q1 2026 at Structure Therapeutics, down from $177.1 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $177.1 million in Q4 2025 to a low of -$76.0 million in Q1 2026.
• Historically, Net Income has averaged -$14.1 million across 5 years, with a median of -$23.9 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Net Income jumped 1247.36% in 2023, then tumbled 149.4% in 2024.
• A 5-year view of Net Income shows it stood at -$4.8 million in 2022, then surged by 1247.36% to $55.4 million in 2023, then sank by 149.4% to -$27.4 million in 2024, then surged by 746.99% to $177.1 million in 2025, then plunged by 142.9% to -$76.0 million in 2026.
• The last three Net Income figures came in at -$76.0 million (Q1 2026), $177.1 million (Q4 2025), and -$65.7 million (Q3 2025), per Business Quant data.